N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Melanoma
Both
Melanoma
Trial Information
Inclusion Criteria
Inclusion criteria
- Pathologically-proven diagnosis of melanoma.
- Patient must have a test or procedure that has the potential to provide left-over
tissue that can be banked for future research purposes OR the patient has already had
a diagnostic or therapeutic procedure but who has not yet been approached to
participate is also eligible.
Exclusion criteria
- Any patient with significant contraindications to venipuncture (e.g., severe anemia)
will be excluded from blood collection procedures. However, if the patient provides
consent and a paraffin-embedded block or 10-15 unstained slides of their tissue
diagnosis, they will not be excluded from this protocol.
- Any patient unable or unwilling to provide consent.
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Outcome Measure:
Molecular changes in patients' melanoma tissue
Outcome Description:
Tissue is collected upon consent or upon receipt of parafin block, primary aim will be met when all tissues are collected and analyzed at conclusion of study. Intent is to aid patients and their treating physician when making treatment decisions.
Outcome Time Frame:
at 120 months
Safety Issue:
No
Principal Investigator
Jeffrey Sosman, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Vanderbilt-Ingram Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
VICC MEL 09109
NCT ID:
NCT01205815
Start Date:
June 2010
Completion Date:
January 2020
Related Keywords:
- Melanoma
- Melanoma
Name | Location |
|---|---|
| Vanderbitl-Ingram Cancer Center | Nashville, Tennessee |
